Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NKTX
NKTX logo

NKTX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Nkarta Inc (NKTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
2.130
1 Day change
3.90%
52 Week Range
2.810
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Nkarta Inc (NKTX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The lack of positive financial performance, insider selling, and absence of strong trading signals or catalysts make it unsuitable for investment at this time.

Technical Analysis

The MACD is negatively expanding (-0.0528), RSI is at 27.094 (neutral zone), and moving averages are converging, indicating no clear upward momentum. The stock is trading near its support level (S1: 2.167) with weak technical indicators.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The low Open Interest Put-Call Ratio (0.2) indicates bullish sentiment, but the high Option Volume Put-Call Ratio (1.83) suggests bearish trading activity in the short term.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
6

Positive Catalysts

  • NULL identified. No recent news or events to drive positive sentiment.

Neutral/Negative Catalysts

  • Insiders are selling heavily, with a 1947.69% increase in selling activity over the last month. The company's financials show declining net income (-23.39% YoY) and EPS (-25.64% YoY).

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net income drop to -$21.72M (-23.39% YoY), and an EPS decline to -0.29 (-25.64% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for review.

Wall Street analysts forecast NKTX stock price to rise
5 Analyst Rating
Wall Street analysts forecast NKTX stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.050
sliders
Low
10
Averages
12.33
High
16
Current: 2.050
sliders
Low
10
Averages
12.33
High
16
Stifel
Buy
downgrade
$12 -> $11
AI Analysis
2025-11-11
Reason
Stifel
Price Target
$12 -> $11
AI Analysis
2025-11-11
downgrade
Buy
Reason
Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.
Stifel
Stephen Willey
Buy
downgrade
$14 -> $12
2025-08-14
Reason
Stifel
Stephen Willey
Price Target
$14 -> $12
2025-08-14
downgrade
Buy
Reason
Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NKTX
Unlock Now

People Also Watch